Investigational antiarrhythmic drugs for the treatment of ventricular rhythm disturbances.
Currently available antiarrhythmic drugs possess very poor therapeutic-to-toxic ratios, and therefore, there is a great deal of interest in the development of new investigational agents to suppress ventricular rhythm disturbances. This article includes most of the investigational ventricular antiarrhythmic drugs in which there has been a great deal of recent active investigation and interest. It stresses the different patient populations that have been tested with each of these antiarrhythmic drugs, pointing out those drugs that have been documented to be effective in nonsustained ventricular tachycardia or sustained ventricular tachycardia and sudden cardiac death.
D000638:Amiodarone / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D001073:Aprindine / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D016700:Encainide; D005424:Flecainide; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008012:Lidocaine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008801:Mexiletine / Q000627:therapeutic use; D016293:Moricizine; D010640:Phenothiazines / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D016677:Tocainide
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D010640:Phenothiazines; D010880:Piperidines; D008801:Mexiletine; D016677:Tocainide; D016293:Moricizine; D001073:Aprindine; D008012:Lidocaine; D005424:Flecainide; D000638:Amiodarone; D007099:Imipramine; D016700:Encainide